Patent prosecution, FTO analysis, licensing vs. equity pathways — all informed by regulatory timelines. IP is the root system from which everything else grows.
FDA pathway design pre-IND through approval, IND/NDA submissions, pharmacovigilance, DSMB establishment. Team: 20+ years at Genentech, Nektar, Celgene.
Device concept through FDA clearance, design for manufacturing, prototyping — regulatory classification integrated from Day 1, not retrofitted.
Clinical-stage biotech development, translational research commercialization, venture creation. Biotech CEO experience. Columbia-trained commercialization.
44 years placing C-suite talent in biotech, pharma, and medical devices. Governance designed before talent is deployed — not after the damage is done.
Performance-contingent company building with equity participation from formation through seed stage. Portfolio: VectorGen, Apex Protocol.
Our Philosophy
Infrastructure
Deployed Upstream.
In life sciences, sequence matters. IP strategy must inform the regulatory pathway. The regulatory pathway must inform clinical design. Clinical design must inform product specifications. Commercialization timelines must inform leadership deployment.
When these decisions are made in silos by disconnected specialists, structural failure is inevitable. When they are integrated by a single partner who understands the complete path from lab to market, breakthrough science actually reaches the world.
"Founders don't fail for lack of ambition or expertise. They fail for lack of integrated execution infrastructure deployed at the right time."